Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in
cancer treatment. It is based on genetically modified T cells to express a CAR, which …

T cells, natural killer (NK) cells, macrophages (Macs), and dendritic cells (DCs) are among
the most common sources for immune-cell-based therapies for cancer. Antitumor activity can …

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life
expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute …

Intra-tumoral immune cells promote the stemness of cancer stem cells (CSCs) in the tumor
microenvironment (TME). CSCs promote tumor progression, relapse, and resistance to …

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative
potential and become a critical component in the array of B-cell malignancy treatments …

Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic
efficacy in the clinic and can even mediate curative responses in patients with hematologic …

The development of methods to derive induced pluripotent stem cells (iPSCs) has propelled
stem cell research, and has the potential to revolutionize many areas of medicine, including …